Yaman Tokat

Prof. Dr. Yaman Tokat


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Hepatology
Verified
Journal Article
Open access
DHDebashis Haldar
Debashis Haldar
BKBarbara Kern
Barbara Kern
JHJames Hodson
James Hodson
MAMatthew James Armstrong
Matthew James Armstrong
RARene Adam
Rene Adam
SSStefan Schneeberger
Stefan Schneeberger
Little is known about outcomes of liver transplantation for patients with non-alcoholic steatohepatitis (NASH). We aimed to determine the frequency and outcomes of liver transplantation for patients with NASH in Europe and identify prognostic factors. We analysed data from patients transplanted for end-stage liver disease between January 2002 and December 2016 using the European Liver Transplant Registry database. We compared data between patients with NASH versus other aetiologies. The principle endpoints were patient and overall allograft survival. Among 68,950 adults undergoing first liver transplantation, 4.0% were transplanted for NASH - an increase from 1.2% in 2002 to 8.4% in 2016. A greater proportion of patients transplanted for NASH (39.1%) had hepatocellular carcinoma (HCC) than non-NASH patients (28.9%, p 65: HR 1.72, p = 0.017), elevated model for end-stage liver disease score (>23: HR 1.48, p = 0.048) and low (40 kg/m2: HR 1.96, p = 0.012) recipient body mass index independently predicted death in patients transplanted for NASH without HCC. Data must be interpreted in the context of absent recognised confounders, such as pre-morbid metabolic risk factors. The number and proportion of liver transplants performed for NASH in Europe has increased from 2002 through 2016. HCC was more common in patients transplanted with NASH. Survival of patients and grafts in patients with NASH is comparable to that of other disease indications. The prevalence of non-alcoholic fatty liver disease has increased dramatically in parallel with the worldwide increase in obesity and diabetes. Its progressive form, non-alcoholic steatohepatitis, is a growing indication for liver transplantation in Europe, with good overall outcomes reported. However, careful risk factor assessment is required to maintain favourable post-transplant outcomes in patients with non-alcoholic steatohepatitis.

30 July 2008 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
CTC. Burcin Taner
C. Burcin Taner
MDMurat Dayangac
Murat Dayangac
BABaris Akin
Baris Akin
DBDeniz Balci
Deniz Balci
SUSuleyman Uraz
Suleyman Uraz
Yaman TokatYaman Tokat
Yaman Tokat
Living donor liver transplantation is now a common practice in countries in which the availability of cadaveric organs is limited. The preoperative preparation, intraoperative surgical technique, and postoperative care of donors and recipients have evolved in recent years. We retrospectively compared 67 donors with a remnant liver volume equal to or more than 30% (group 1) with 14 donors who had less than 30% remnant liver volume (group 2) for donor outcomes. All the complications in donors were systematically classified. Donors with less than 30% remnant liver volume showed significantly higher peak aspartate aminotransferase, alanine aminotransferase, international normalized ratio, and bilirubin levels. There were 6 complications in group 1 and 4 complications in group 2. The difference between the 2 groups in terms of donor complications did reach statistical significance (P = 0.043); donors with a remnant liver volume < 30% had a 4 times greater relative risk of morbidity. In conclusion, the use of donors with less than 30% remnant liver volume is highly debatable as donor safety should be of utmost importance in living donor liver transplantation. Liver Transpl 14:1174–1179, 2008. © 2008 AASLD.

9 October 2003 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
SUSezgin Ulukaya
Sezgin Ulukaya
ÇAÇidem Arıkan
Çidem Arıkan
SASema Aydodu
Sema Aydodu
HAHilmi Omer Ayanoglu
Hilmi Omer Ayanoglu
Yaman TokatYaman Tokat
Yaman Tokat

3 October 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MHMelina Heinemann
Melina Heinemann
TLTimur Liwinski
Timur Liwinski
RARene Adam
Rene Adam
MBMarina Berenguer
Marina Berenguer
DMDarius Mirza
Darius Mirza
CSChristoph Schramm
Christoph Schramm
Knowledge of living donor liver transplantation (LDLT) for autoimmune liver diseases (AILDs) is scarce. This study analyzed survival in LDLT recipients registered in the European Liver Transplant Registry with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis (PSC) and the non-autoimmune disorder alcohol-related cirrhosis. In total, 29902 individuals enrolled between 1998 and 2017 were analyzed, including 1003 with LDLT. Survival from >90 days after LDLT for AILDs in adults was 85.5%, 74.2%, and 58.0% after 5, 10, and 15 years. Adjusted for recipient age, sex, and LT era, adult PSC patients receiving LDLT showed increased mortality compared to donation after brain death (DBD) (hazard ratio [HR]=1.95, 95%-confidence interval [CI]=1.36–2.80, p90 days after LDLT compared to DBD (HR=3.00, 95%-CI 1.04–8.70, p=0.043). Multivariate analysis identified several risk factors for death in adult PSC patients receiving LDLT including a male donor (HR=2.49, p=0.025). Adult PSC patients with LDLT versus DBD conferred increased mortality from disease recurrence (subHR=5.36, p=0.001) and biliary complications (subHR=4.40, p=0.006) in multivariate analysis. While long-term outcome following LDLT for AILD is generally favorable, PSC patients with LDLT compared to DBD might be at increased risk of death.

13 June 2012 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
OYOnur Yaprak
Onur Yaprak
MAMurat Akyildiz
Murat Akyildiz
MDMurat Dayangac
Murat Dayangac
BDBaha Tolga Demirbas
Baha Tolga Demirbas
NGNecdet Guler
Necdet Guler
Yaman TokatYaman Tokat
Yaman Tokat

1 July 2015 in Transplantation
Verified
Journal Article
Closed access
AOArzu Oezcelik
Arzu Oezcelik
MDMurat Dayangac
Murat Dayangac
NGNecdet Guler
Necdet Guler
OYOnur Yaprak
Onur Yaprak
YEYalcin Erdogan
Yalcin Erdogan
Yaman TokatYaman Tokat
Yaman Tokat
Previous published studies have shown that age is not a contraindication for deceased donor liver transplantation. The data about elderly recipient after living donor liver transplantation (LDLT) is unsatisfactory. The aim of this study was to evaluate the outcome of the LDLT with recipients aged 70 years or older. Between 2005 and 2013, 469 patients underwent LDLTs. The clinical characteristics, preoperative, intraoperative, and postoperative data, graft, and patients' survival of these patients were retrospectively analyzed. All recipients who were 70 years or older at the time of liver transplantation were indentified. The results were compared to the results of the patients younger than 70 years. There were 12 patients (2%) 70 years or older. All patients received the right lobe of their donor in a standard technique. One patient died postoperatively because of pulmonary infection, and one patient died 6 months after the operation because of graft failure after cardiac infarction. The comorbidity score of these two patients were significantly higher compared to the other ten patients without any complications (8.5 vs. 4.6, P = 0.01). The 1-year and 3-year patient and graft survival was 84%. There were no significant differences in complications, hospital stay, perioperative mortality, or median survival compared to the younger group. Although the number of the patients is small, our study emphasizes that LDLT of patients 70 years or older can be performed safely in patients without major comorbidities. Elderly patients with increased risk for postoperative complications should be excluded from LDLT.